This ambitious meta-analysis into cardiac stem cell therapy has been widely covered in the media, including in a Nature editorial. Other articles covering our meta-analysis include Forbes' article, "Stem Cell Therapy To Fix The Heart: A House Of Cards About To Fall?"
Early renal denervation trials showed office blood pressure reductions of ~30 mmHg, yet reductions in ambulatory blood pressures appear to be several-fold smaller. This paper correctly predicted, through meta-analysis of drug trials, the startlingly lower results seen in the landmark SYMPLICITY-HTN 3 trial. Our work has been covered by Forbes, Medscape and the Motley Fool
International Journal of Cardiology
After CONVERGE and Symplicity-HTN 3 demonstrated a huge disparity between results from unblinded/uncontrolled trials and the gold-standed double-blinded RCT trials, we wrote this paper to explain why and how researchers should minimise the effects of bias when designing hypertension trials.
An editorial published in the BMJ following the findings from the Symplicity-HTN 3 trial, re-iterating the importance of good trial design in hypertension.
We investigated the safety and feasibility of very early discharge 2 days following PPCI in selected low risk STEMI patients. Our data suggest that discharge of such patients two days after successful PPCI is feasible and safe. Over 40% of all patients with STEMI may be suitable for early discharge with important implications for healthcare costs.
Expert Review of Clinical Pharmacology
This review covers the evidence for anti-platelets and anti-coagulants in ACS
An educational review and case series of constrictive pericarditis patients, emphasising how this disease may manifest in a variety of ways, leading to misdiagnosis. We covered two patients who were initially wrongly diagnosed as having hepatic or respiratory diseases.
Total publications: 21
Total citations: 150